Key Highlights
- LSE:OXB gained 6.02% on 22 September 2026, closing at 493p, after trading between 449p and 498p. Volume was approximately 946,000 shares.
- Oxford Biomedica reported 9% reported Revenue growth to £79.8 million in H1 2026, with constant-currency revenue up 10% to £80.2 million.
- The company signed 17 new clients during H1 2026, more than 30% above the total number signed during FY2025.
- Revenue Backlog reached approximately £193 million, with around £168 million of forecast FY2026 revenue covered by contracted client orders as of September.
- Adjusted operating EBITDA loss narrowed to £2.5 million from £3.9 million a year earlier.
- Oxford Biomedica reiterated FY2026 constant-currency revenue guidance of £180 million–£200 million.
- Management continues to target 25%–30% revenue growth in FY2027.
- The Durham, North Carolina GMP Manufacturing Facility is now online, with its first GMP manufacturing run completed.
Why Did Oxford Biomedica Shares Rise 6.02% on 22 September 2026?
Oxford Biomedica became one of the most closely watched UK healthcare stocks on 22 September after LSE:OXB climbed 6.02% to 493p. The move followed the company's interim results for the six months ended 30 June 2026, which highlighted continued revenue growth, record new-client activity and improving EBITDA performance.
The market reaction came despite the company remaining loss-making. Instead, attention was focused on the improving commercial indicators supporting Oxford Biomedica's longer-term growth strategy.
The company is a contract development and manufacturing organisation focused on cell and gene therapy, providing development and manufacturing services to biotechnology and pharmaceutical customers.
The latest results showed that the customer pipeline continued to expand, while the opening of the Durham facility provides additional manufacturing capacity for future programmes.
What Did Oxford Biomedica Report in H1 2026?
Revenue increased from approximately £73.2 million in H1 2025 to £79.8 million, representing 9% reported growth and 10% growth at constant currency.
However, the company's statutory loss remained significant. The reported net loss widened to approximately £37.0 million, compared with £26.4 million a year earlier.
This creates an important distinction for investors: Oxford Biomedica is currently being assessed largely on its revenue growth, client wins, backlog, manufacturing capacity and future profitability trajectory, rather than current net earnings.
Adjusted operating EBITDA improved to a loss of £2.5 million, compared with a £3.9 million loss in H1 2025. The improvement reflects stronger revenues and continued cost discipline.
Why Are New Client Wins Important for LSE:OXB?
One of the strongest indicators in the latest update was Oxford Biomedica's commercial momentum.
The company signed 17 new clients during H1 2026, which was more than 30% higher than the total number of new clients secured throughout FY2025. A further four clients were signed after the reporting period.
The company said its total client portfolio had reached 50 clients and 59 client programmes.
This matters because CDMO revenue can build over time as customer programmes move through development, clinical and commercial stages. Consequently, new contracts can create a pipeline of future manufacturing work rather than simply adding immediate-period revenue.
What Does Oxford Biomedica's £193 Million Backlog Mean?
Revenue visibility has become another major focus for LSE:OXB.
Oxford Biomedica reported a revenue backlog of approximately £193 million at 30 June 2026. By September, around £168 million of forecast FY2026 revenue was covered by contracted client orders.
The company also reported that its non-risk-adjusted new-business pipeline had expanded by approximately 30% year-on-year to around £539 million.
The combination of backlog and pipeline provides investors with indicators of future demand, although pipeline value should not be treated as equivalent to secured revenue because individual programmes can change, be delayed or Fail to progress.
Why Is the Durham Facility Important for Oxford Biomedica?
The company's Durham, North Carolina facility is becoming an increasingly important part of its expansion strategy.
Oxford Biomedica confirmed that GMP manufacturing capabilities at Durham are now online and that the first GMP run has been completed. Client activity is expected to increase during H2 2026 after previously disclosed remedial work was completed.
The facility expands Oxford Biomedica's manufacturing footprint in the United States and is designed to support clients developing advanced therapies.
For investors, the key issue is now execution: the facility needs to move from commissioning and initial manufacturing into a higher utilisation phase capable of contributing materially to revenue and profitability.
What Is Oxford Biomedica's FY2026 and FY2027 Outlook?
Oxford Biomedica reiterated its FY2026 constant-currency revenue expectation of £180 million–£200 million. The company also expects a mid-single-digit EBITDA Margin excluding one-off costs and a low-single-digit margin on a reported basis.
Looking further ahead, management continues to expect 25%–30% revenue growth in FY2027.
The longer-term ambition remains approximately £500 million of revenue by 2030, with EBITDA margins eventually approaching approximately 30% as scale and operational Leverage increase.
These targets make future revenue conversion and margin expansion particularly important indicators for investors monitoring LSE:OXB.
Why Is Oxford Biomedica in Focus for Investors Now?
The latest share-price move has brought several themes into focus.
The first is the record pace of new-client acquisition. The second is the growing backlog and pipeline. The third is the transition of the Durham facility into commercial production.
Investors will also be watching whether revenue growth eventually translates into consistent EBITDA profitability because the company remains loss-making at the statutory level.
Gross margin declined to 37% from 43% in H1 2025, with Oxford Biomedica attributing the movement to product and client mix as well as one-off comparative effects.
That makes margin progression one of the most important metrics alongside revenue growth.
What Should Investors Watch Next for LSE:OXB?
Key areas include:
- Conversion of the £193 million revenue backlog.
- Delivery against the £180 million–£200 million FY2026 revenue target.
- New-client additions during H2.
- Utilisation of the Durham GMP facility.
- Gross-margin recovery.
- EBITDA improvement.
- Development of the approximately £539 million new-business pipeline.
- Progress toward 25%–30% FY2027 revenue growth.
- Cash usage and funding requirements.
- Expansion of late-stage and commercial-stage client programmes.
- Progress toward the longer-term £500 million revenue ambition.
The 6.02% gain on 22 September 2026 therefore followed a combination of stronger revenue, record client acquisition, improved adjusted EBITDA performance and growing revenue visibility.
The key question for the next phase is whether Oxford Biomedica can convert its expanding client base and manufacturing capacity into sustained revenue growth and materially stronger profitability.






Please wait processing your request...